Searchable abstracts of presentations at key conferences in endocrinology

ea0091wa15 | Workshop A: Disorders of the hypothalamus and pituitary | SFEEU2023

Macroprolactinoma in a young male; a cause of delayed puberty

Foteinopoulou Evgenia , Wright Rohana

A 19 year old male was referred urgently due to a significantly raised Prolactin. He had seen his GP due to a cough, who then noted the patient had not progressed through puberty and organized further testing. On examination he had a BMI of 47. His height was 178 cm with a target of 184.5 cm (range 176-193). He had bilateral gynaecomastia with micropenis and pre-pubertal testes. He had never shaved and his voice was high-pitched. He did not report anosmia. Visual fields were n...

ea0062we9 | Workshop E: Disorders of the gonads | EU2019

Male hypogonadotrophic hypogonadism; fitting fertility with life

Foteinopoulou Evgenia , Anderson Richard

A 33-year-old male with a background of idiopathic hypogonadotrophic hypogonadism was referred to the endocrine clinic to discuss fertility. He was originally diagnosed overseas when presented with delayed puberty in late teens. He had a normal pituitary MRI and since then he had been on testosterone replacement; other pituitary function was normal. He was not anosmic however no other information was available from diagnosis. When he attended the clinic the patient and his wif...

ea0059ep44 | Clinical practice, governance & case reports | SFEBES2018

Iatrogenic Cushings secondary to inhibition of triamcinolone metabolism by cobicistat

Foteinopoulou Evgenia , Ritchie Stuart

Background: CYP3A4 is the most prevalent cytochrome P450 (CYP) enzyme in the liver, and is used by the majority of medications for their metabolism and elimination from the body. The inhibition of CYP3A4 can result in the accumulation of drug concentrations increasing the risk for possible toxicity. We report a case of iatrogenic Cushings’s syndrome secondary to impaired CYP3A4 metabolism of triamcinolone by coadministration of darunavir/cobicistat, with resultant seconda...

ea0055cb10 | Additional Cases | SFEEU2018

A 60 year history of recurrent hypoglycaemia

Foteinopoulou Evgenia , Colclough Kevin , Strachan Mark

A 69 year old male was referred with a 60 year history of recurrent hypoglycaemia. Over the previous 12 months he had several episodes of severe hypoglycaemia, which necessitated emergency treatment from paramedics. He had been diagnosed with a hypoglycaemic disorder at the age of 9 years, but no underlying cause had been identified. He had no other previous history of note, though he was macrosomic at birth with a birth weight of approximately 5.9 kg. His mother was diagnosed...

ea0041ep127 | Bone & Osteoporosis | ECE2016

State of bone mineral density in children with Turner Syndrome in Ukraine

Zelinska Nataliya , Shevchenko Iryna , Globa Evgenia

Background: Low bone mineral density (BMD) and osteoporosis are the frequent consequences of Turner Syndrome (TS).Objective and hypotheses: We examined the BMD in TS girls with different age and karyotype.Methods: Measurements of BMD (g/cm2), Z-score (S.D.) were conducted in 26 girls using X-ray absorptiometry (DEXA) at the lumbar spine L2–L4 depending on the child’s age.<p class="ab...

ea0041ep128 | Bone &amp; Osteoporosis | ECE2016

Osteocalcin as a marker of bone metabolism disorders in girl with Turner syndrome

Zelinska Nataliya , Shevchenko Iryna , Globa Evgenia

Background: One of the markers of bone metabolism is osteocalcin (OC) and Its elevated level indicates osteoporosis.Objective and hypotheses: We investigated the OC level in 14 girls with TS (45,X (n=8), 45,X/46,XX (n=3), structural abnormalities of chromosome X (n=3): seven patients at 4–11 year and 7 – at 12–18 year.Method: DEXA (Z-score, S.D.), serum levels of OC,...

ea0063p270 | Pituitary and Neuroendocrinology 1 | ECE2019

Assessment of endocrine function before and after transsphenoidal surgery for Cushing s disease

Kolesnicova Galina , Arapova Svetlana , Marova Evgenia , Grigoriev Andrey

It is known that disoaders of the hypothalamic-pituitary-adrenal system and excess glucocorticoids in Cushing’s disease (CD) can significantly affect various organs and systems, in particular, the secretion of pituitary hormones. However, in the literature there is practically no work on the assessment of the state of tropic hormones and hormones of the peripheral glands in the early postoperative period after transsphenoidal adenomectomy. The aim of this study was to ass...

ea0049ep905 | Neuroendocrinology | ECE2017

MR-characteristics as predictors of pituitary adenomas hormonal and proliferal activity

Krivosheeva Yulya , Dreval Alexander , Panteleeva Evgenia , Stashuk Galina , Ilovayskaya Irena

Introduction: Previous studies demonstrated a relationship between T1- and T2-weighted signal intensity and tumor growth pattern in pituitary somatotropinomas. The goal of this retrospective study was to analyze the MRI characteristics of pituitary macroadenomas with different hormonal activity in newly diagnosed patients.Material and methods: Pre-treatment T1- and T2-weighted MR-images (Intera Achieva, PHILIPS, 3.0T) of patients with 42 non-functional a...

ea0041ep927 | Pituitary - Clinical | ECE2016

Results of transsphenoidal surgery and somatostatin analogues therapies and their combination in acromegaly

Trigolosova Irina , Dreval Alexander , Panteleeva Evgenia , Molchanova Galina , Chikh Irina

Introduction: Data on transsphenoidal surgery (TSS) and effect of somatostatin analog therapy (SSA) in acromegaly different among medical centers. We analyzed the data on TSS, SSA and their combination in acromegalic patients of Moscow region.Design: In this study 117 acromegalic patients (25 males and 92 females, 55.0 (IQR 44 – 62) years) were eligible for participation, of whom 34 were newly-diagnosed aromegaly (NA group) (macroadenoma (macro)- 80...

ea0032p872 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Ursodeoxycholic acid role in chronic cholecystitis progression prevention in acromegaly patients receiving somatostatin analogues

Poteshkin Yuriy , Pronin Vyacheslav , Pronin Evgeny , Kotlyarevskaya Evgenia , Morozova Maria

Introduction: Acromegaly – a serious debilitating disease resulting in decreased quality and length of life. Due to the late nature of the diagnosis, the lack of prospects for a surgical or non-radical adenomectomy leads to a somatostatin analogues (SA) treatment as primary or secondary therapy, which is a long-term, sometimes lifelong. Therefore, the question of tolerability and prevention of life-threatening complications for these patients is very important. Since the ...